MAIN MENU
QUICK LINKS
CONNECT WITH US

Button
Coronavirus (COVID-19) updates, visitor restrictions and resources →
Now offering telemedicine through our Virtual Visit online program for primary care and specialty care visits → Virtual Visit appointments are available for new and existing UF Health patients. Check the FAQ section and Request an Appointment section below for more information.

Call (904) 383-1052 to make an appointment or call your physician’s office if you have questions specific to your health needs.

Clinical Trial Details

Title
D1699C00001: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction
Study Description

This research study is carried out to see if dapagliflozin is effective in heart failure by reducing the number of hospitalizations due to heart failure, or worsening of heart failure events, and in the long run to improve the survival for patients with heart failure.

In this study you will receive either dapagliflozin or a placebo (inactive medication) in addition to your current heart failure medication. The placebo tablet will look identical to a dapagliflozin tablet and you will not know during the study whether you are receiving active dapagliflozin or the placebo tablet. You are expected to remain in this study from about 1 to 3 years depending on when you enter the study.

Open Enrollment
Contact Name: Andrea Goosen
Contact Phone: (904) 244-5617
Contact Email: Andrea.Goosen@jax.ufl.edu
Investigators

Principal Investigator
Francesco Franchi, M.B.Ch.B. (M.D.)
Medicine

Sub Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC
Medicine

Sub Investigator
Fabiana Rollini, M.B.Ch.B. (M.D.)
Medicine